報價延遲最少15分鐘:2026/05/13 10:56 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
24.48 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.25/-2.34
|
|
企業價值
808.50M
|
| 資產負債 |
|
每股賬面淨值
-2.96
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company isdeveloping two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery. |
